SM
ALNY icon

SG3 Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

SG3 Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,000
Closed -$2.59M – 932
2021
Q4 		$2.88M Sell
17,000
-23,250
-58% -$4.32M 0.06% 272
2021
Q3 		$7.6M Buy
40,250
+35,250
+705% +$6.61M 0.23% 81
2021
Q2 		$848K Buy
5,000
+1,000
+25% +$146K 0.03% 518
2021
Q1 		$565K Buy
+4,000
New +$602K 0.01% 741

Other funds holding ALNY

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

SG3 Management's ALNY Position: Q1 2022 in Review

SG3 Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 17,000 shares — an estimated $2.59M sold.

SG3 Management first reported a position in ALNY in Q1 2021 and held it in 4 quarters. The position peaked at $7.6M in Q3 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • SG3 Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 17,000 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $2.59M.
  • SG3 Management first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • SG3 Management's Alnylam Pharmaceuticals position peaked at $7.6M in Q3 2021.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.